Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6044863 | 1.00 | CYP3A4 (0.33) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL6045233 | 0.88 | HSD17B10 (0.33) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL6045399 | 0.88 | HSD17B10 (0.33) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL9634771 | 0.75 | PIK3CD (0.40) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL8779711 | 0.75 | CYP3A4 (0.33) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| Hydrochloric Acid SCHEMBL29209657 | 0.72 | PTPN1 (0.32) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL31326051 | 0.71 | DPP4 (0.34) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL4703842 | 0.68 | HSD17B10 (0.36) | — | |
| SCHEMBL1114602 | 0.68 | CYP3A4 (0.44) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL6204993 | 0.66 | HTT (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | ELAN PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | claimed |
| EP-0678503-B1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | NOVARTIS AG (CH) | 1999-09-01 | — | — | EP | claimed |
| US-5559111-A | HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren | CIBA-GEIGY CORPORATION (US) | 1996-09-24 | — | — | US | claimed |
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | ELAN PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | BACE1, APP, PSEN1 | CYP3A4 1974/4885TSHR 876/4885TDP1 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.